Caicun Zhou

Stories

Antibody-drug conjugate combination outperforms chemo-immunotherapy in PD-L1-negative lung cancer

Presented OptiTROP-Lung06 results at ESMO 2026 (LBA66)

Pairing an antibody-drug conjugate with pembrolizumab kept advanced lung cancer from worsening for a median of 15 months, nearly three times as long as the standard pembrolizumab-plus-chemotherapy regimen. The Phase III OptiTROP-Lung06 results were presented on October 25 at the ESMO congress in Madrid and published the same day in the New England Journal of Medicine.

Updated Oct 27